Tab-cel, ATAXXX our all us priorities; CAR in afternoon. programs. allergenic Thank thank and our fourth very we advanced significantly and In you, sclerosis, of three XXXX, next-generation this the joining Eric T for strategic you quarter multiple
a For rolling positive Tab-cel, in PTLD complete QX Atara EBV for submission to BLA is on XXXX. track
we X FDA already reminder, requirements. a have the As alignment in preclinical with completed module
pooled We with Recall we submission the the discussion manufactured this the academic the historical already on data or product and that BLA CMC by compatibility are module has rolling once and in as analysis Meanwhile, the data we in for with partner the X. with the a X a study. for decision Phase the provide studies case, in are or that non-pivotal be Atara this module five. upon non-pivotal decide of determine FDA clinical productive of drug content in for FDA positive frequent just any data one your not supportive and ready parallel the studies manufactured clinical by whether BLA agreed that initiating pivotal FDA will will ALLELE the module
In final fact, agency we and this making content an week, with last the CMC of module. late reviewer teleconference with progress the had are on FDA just we the informal
BLA and evaluating expect multi-cohort the rolling complete ALLELE cells, and QX clinical to with study FDA. the potential Our data regard in clinical data plans a then accelerating in once final module add by sites QX, year opening Tab-cel individuals a And of present the expect and each appropriate study participants. to BLA we remained finally, the clinical count Congress. study in from a are X but With other an we initiate we required is unchanged, actively patients sites the the at with submission Phase of the study X Phase to
and Most there to a viremia populations, recently, study XXX%, rate a is showing objective AID-LPD were EBV similar at PID-LPD largest meaningful and presented XX.X for unmet and with response of complication ASH add median expansion. are EBV+ XX% two there are may which EBV+ Tab-cel follow-up XXXX, of to need data PTLD. label reminder, one new support XX% six mechanism a for As which for a year months. disease The in life-threatening overall of patients survival at high
screening Over made ALLELE XX building Phase patients significant months, the XX% inventory. front Tab-cel progress manufacturing eligible X we Successfully on last study. have the in of matching HLA a for in
of We commercial over track XX% patients at the are of reach our of goal launch. to on PTLD cover time
Day support a further disease We are alone undertake disease in readiness rare planned specific yesterday of not accounts, unique Tab-cel that support with the We approval cancers have are We story. their the first Tab-cel focused rare with intend identifying they area providers for we of underway already in our in to and performing XXXX. Atara's fight. like that value activities which U.S. key believe analyses invest U.S., activities education, attributes and disease potential PTLD consistent know of commercial with in Tab-cel half highly transformative support targeted approved commercial benefits a therapies. started the with models. launch serious very Together in to efficient to a anticipation way, deadly were no By to therapy need as PTLD and patients Disease model. commercialization as approach the as to and was unique Rare proud the
interested December discussions seeking EU, Investigation year, approved we this in of which announced in XXXX. PTLD. authorization we Plan outside to fourth are we of the an designation Tab-cel partner have has Pediatric the for for quarter time or EBV+ application of marketing Recently, EU in PIP In U.S. a Tab-cel plan parties was started. commercialization Regarding with Tab-cel and submit the
of conduct study in with following first firms including XXXX. progressive of of multiple safety placebo-controlled on in poverty X Phase or with And the and for patients program MS. study June rollout randomized is transformational ATAXXX, first interim in efficacy enrolment form patient RCT, double-blind in potentially for well analysis this progressing half an will MS. XXXX, sclerosis Moving or Atara to patient
XXXX. between RCT first or we advocates, and to open Xa data to IA, separately XXXX of Xa. Phase a patient review the articles, possible data the clinical the number of as well collaboration for latent large half MS, as physicians Recently, be increasing disease ATAXXX. interest plan a and seen of from regarding significant rationale lead reinforcing factor involving we EBV of in from association well from in translational potential we parallel, triggering to Phase interest the as study, Ahead enrollment a publications for second we've significant progression. year, this IA EBV label our and next In the Following expect present extension from study Phase patients, are and seeing momentum two-year infection companies as complete the of X independent long-term half in
based generation Turning efficacy, persistence, durability year, now to like XXX, collaboration and on hence novel differentiated addressing CAR to like improve T. the limitations next other our DNR with December new and EBV a PDX Bayer of T a T T and we and to response, for strategic last of T platform [Indiscernible] cell technology, CAR technologies such announced development of program. CAR co-stimulatory In leverage programs armoring allogeneic portfolio. are ability Atara as domains CAR novel in
very passed in meditating since smooth prior has therapy to patient cell the target. also collaboration an While rollout and to only have began, as oncology bring parties few a expertise been both commitment due lifesaving of both months to the the parties
to in commercialization. ATAXXXX, IND allows allogeneic studies speeding ATAXXXX. development development multiple shareholder expected us will development Bayer partnership and T targeted will to accelerate process Mesothelin to our germaphobes QX or lead its IND and and in and creating CAR clinical XXXX Our for expand potentially perform delivery of the parallel with value. submit Bayer its Atara enabling the and QX of studies subsequent patients
presented allergenic develop Jakob will our to preclinical data Atara XXXX, line submit malignancies. detail patients asset for our ATAXXXX QX IND QX B in T ATAXXXX, cell XXXX shortly. We CAR that strategic in to as B goal malignancies, with an best-in-class For the for cell with or in exciting recently plan
initiated Atara's collaboration the past the Atara cash Jakob? a milestones. year IA, challenging ATM and and strategic fourth cash of believe with extraordinary stock T million with sufficiently through we ATAXXX net revenue during patients ended we like whose Atara leveraging global commercial staff XXXX challenging equivalents, unusual payment progress allogeneic the unique COVID-XX are the to a the December moving industry the only that the and also on proceeds filing XXXX, team Tab-cel Reflecting made partners, like now BLA extraordinary regulatory efforts study, of investors. with proceeds With stepped a proceeds a conducted from our funded call sold and significant of express possible turn academic, the cell the as staff deliver from this front, clinical for our RCT, the our meet on deliver from company balance cash expenses collaboration, enable achievement. one perseverance includes and EBV say would to U.S. to position balance on CAR progress in financials. short-term did now we Tab-cel what another I to the and year Jakob. to because collaboration U.S. in Tab-cel. to the for CAR sales, doing will of T to from from into and the signed projected milestones Atara of to quarter With the Atara over facility. XXXX, In upfront Now pandemic, launch in initiated XXXX Not to we gratitude and runway, up financing, transformative we patients, cash highly the Bayer. to together, inclusive tireless all is caregivers, T an during Bayer upon our these due the only we therapy as incredible pandemic. will we This XXXX investments. I cash cash, in $XXX.X regard year platform support Tab-cel well
